Ultragenyx Pharmaceutical (NASDAQ:RARE) released its quarterly earnings results on Thursday. The biopharmaceutical company reported ($1.62) EPS for the quarter, missing analysts’ consensus estimates of ($1.61) by ($0.01), Bloomberg Earnings reports. The company had revenue of $35.59 million for the quarter, compared to the consensus estimate of $32.31 million. Ultragenyx Pharmaceutical had a negative return on equity of 52.16% and a negative net margin of 470.18%.
Shares of RARE traded down $1.71 during mid-day trading on Friday, hitting $61.19. The company’s stock had a trading volume of 37,752 shares, compared to its average volume of 586,843. The company has a debt-to-equity ratio of 0.04, a current ratio of 6.79 and a quick ratio of 6.64. The firm has a 50-day moving average price of $53.58 and a 200 day moving average price of $47.87. Ultragenyx Pharmaceutical has a fifty-two week low of $35.41 and a fifty-two week high of $74.50. The stock has a market capitalization of $3.63 billion, a price-to-earnings ratio of -8.46 and a beta of 2.35.
In related news, SVP Theodore Alan Huizenga sold 1,000 shares of the stock in a transaction that occurred on Tuesday, January 14th. The shares were sold at an average price of $61.00, for a total transaction of $61,000.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. 7.80% of the stock is owned by insiders.
Ultragenyx Pharmaceutical Company Profile
Ultragenyx Pharmaceutical, Inc is a biopharmaceutical company, which engages in the identification, acquisition, development and commercialization of novel products for the treatment of serious rare and ultra-rare genetic diseases. Its product includes Mepsevii and Crysvita. The company was founded by Emil D.
Further Reading: What is a stock buyback?
Receive News & Ratings for Ultragenyx Pharmaceutical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ultragenyx Pharmaceutical and related companies with MarketBeat.com's FREE daily email newsletter.